CRSP

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET. A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.comMedia Contact: Rachel Eides WCG on behalf of CRISPR +1-617-337-4167 reides@wcgworld.com

A team of CRISPR scientists in New York say they have identified the genes that can protect human cells against Covid-19.

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the Jefferies London Healthcare Conference on Thursday, November 19, 2020, at 12:00 p.m. ET. A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.comMedia Contact: Rachel Eides WCG on behalf of CRISPR +1-617-337-4167 reides@wcgworld.com

The vote count to decide the next U.S. commander-in-chief is ongoing but healthcare investors do not appear concerned about who will eventually prevail since most industries are up in lockstep

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition ZUG, Switzerland and CAMBRIDGE,

CRISPR Therapeutics (CRSP) reported Q3 results this morning. Fundamentals continue to reflect its clinical-stage status. Funding should not be a near-term concern considering its $1.3B balance of cash (~$1B) and

CRISPR Therapeutics (CRSP): Q3 GAAP EPS of -$1.32 misses by $0.13.Collaboration revenue of $0.15M (-99.9% Y/Y) misses by $2.07M.Cash, equivalents and marketable securities of $1.4B.Shares -3.18% PM.Press Release

CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.32) per share. This is a 155 percent decrease over earnings of $2.40 per share from the same period last year. The company reported $148.00 thousand in